Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–62 of 62 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 mg Psilocybin Clear all

Conditions: Healthy, Psychedelic Experiences, Sleep
Interventions: Psilocybin, Clonidine, Saline; Drug · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 45 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Major Depressive Disorder
Interventions: Psilocybin; Drug
Lead sponsor: COMPASS Pathways; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: La Jolla, California • Jacksonville, Florida • Rockville, Maryland + 2 more

Conditions: Psilocybin
Interventions: Psilocybin, Methylphenidate; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 40 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Alcohol Use Disorder, Alcohol Dependence, Alcohol Abuse
Interventions: Psilocybin, Ketamine; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 21 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Nicotine Dependence
Interventions: Psilocybin-assisted treatment, Nicotine Replacement Therapy (NRT); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2023
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Anhedonia, Emotional Blunting
Interventions: Psilocybin, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: PTSD - Post Traumatic Stress Disorder, PTSD, PTSD Symptoms, PTSD, Post Traumatic Stress Disorder
Interventions: COMP360 psilocybin; Drug
Lead sponsor: COMPASS Pathways; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 15
States / cities: Tucson, Arizona • Irvine, California • Los Angeles, California + 12 more

Conditions: Depression
Interventions: Psilocybin, Transcutaneous Auricular Vagus Nerve Stimulation (taVNS), Sham taVNS; Drug · Device
Lead sponsor: Charles Raison; Other
Eligibility: 18 Years to 70 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Edwards, Colorado

Conditions: Depressive Disorder, Major
Interventions: Psilocybin, Niacin, Set and Setting (SaS) Protocol; Drug · Other
Lead sponsor: Usona Institute; Other
Eligibility: 21 Years to 65 Years
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 11
States / cities: San Francisco, California • Santa Monica, California • New Haven, Connecticut + 8 more

Conditions: Irritable Bowel Syndrome
Interventions: TRYP-0082, Psychotherapy; Drug · Behavioral
Lead sponsor: TRYP Therapeutics; Industry
Eligibility: 21 Years to 64 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Anxiety
Interventions: Psilocybin (drug), Niacin, MRI; Drug · Other · Diagnostic Test
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Torrance, California

Conditions: Mental Health
Interventions: Psilocybin plus mindfulness training, Psilocybin; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 25 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy
Interventions: Psilocybin; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 21 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Psilocybin
Interventions: Psilocybin, Midazolam, Saline; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

Consciousness, Psilocybin, and Well-Being

A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

Precision Functional Brain Mapping in Psilocybin

Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial

Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study

Psilocybin as a Novel Therapy for Residual Anhedonia

Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

Investigation to Understand and Optimize Psilocybin

A Study of Psilocybin for Major Depressive Disorder (MDD)

Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)

Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety

Mindfulness-Assisted Psychedelic Therapy

UW Psilocybin Pharmacokinetics Study

The RECAP2 Study: Midazolam and Psilocybin